TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
Clinical trial NCT04817826 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04817826
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2025-04-30
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.